Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VD's Model Portfolio & Discussion Thread -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (4040)	2/4/1998 11:26:00 PM
From: Cytokine1	Respond to of 9719

VD's MODEL PORTFOLIO 2/4/98 Change -$1491 DOWN -0.63% Started 4/9/97, $100K . INDEX ^IXB DOWN -0.85% VD Inc: Bringing You The Biotech Century # CURRENT DAILY CURRENT COST TOTAL %GAIN/ % OF SYMBOL SHRS PRICE CHANGE %CHG VALUE SHR COST LOSS TOTAL ======= ======= ======= ======= ======= ======= ======= ======= ======= ======= INCY 580 50.38 1.38 2.81% 29218 24.28 14080 107.5% 12.4% CLTR 1000 20.69 -0.56 -2.65% 20688 10.88 10875 90.2% 8.8% GZTC 2770 11.75 0.25 2.17% 32548 7.74 21432 51.9% 13.9% GENZ 530 28.75 -1.13 -3.77% 15238 23.50 12455 22.3% 6.5% AFFX 250 30.75 -0.38 -1.20% 7688 25.77 6441 19.3% 3.3% BGEN 400 40.88 -2.00 -4.66% 16350 35.88 14350 13.9% 7.0% AVIR 500 26.38 0.75 2.93% 13188 25.00 12500 5.5% 5.6% GSII 2700 5.38 -0.13 -2.27% 14513 5.69 15354 -5.5% 6.2% LGND 2800 11.31 0.00 0.00% 31675 12.43 34810 -9.0% 13.5% MOGN 3000 4.31 -0.13 -2.82% 12938 5.125 15375 -15.9% 5.5% ABSC 400 12.50 -0.06 -0.50% 5000 14.94 5975 -16.3% 2.1% GENZL 2015 7.75 -0.25 -3.13% 15616 10.36 20880 -25.2% 6.6% GLFD 500 17.63 -0.88 -4.73% 8813 28.25 14125 -37.6% 3.8% REGN 1000 7.50 0.00 0.00% 7500 12.00 12000 -37.5% 3.2% FUSE 400 9.69 0.94 10.71% 3875 14.19 5675 -31.7% 1.7% SUBTOT ______ ______ ______ ______ 234844 216328 8.6% 100.0% CASH ______ ______ ______ ______ 0 MARGIN MTCE. EQUITY 40.6% MIN 30% (139450) BUYING POWER $ ______ 0 NAV = ______ ______ ______ ______ 95394 100000 -4.6% ^IXB INDEX 310.20 -2.67 -0.85% 302.42 2.6% NOTES: 1/29/98 MDYN sold 500 @ 11.00 ($5500), loss $6250, -53%

To: Biomaven who wrote (4040)	2/10/1998 1:08:00 AM
From: Rocketman	Read Replies (1) \| Respond to of 9719

Monday February 9, 5:24 pm Eastern Time U.S. FDA issues warning on antihistamine WASHINGTON, Feb 9 (Reuters) - Janssen Pharmaceutica and the U.S. Food and Drug Administration (FDA) said on Monday they had issued a warning to doctors about possible drug interactions with the antihistamine Hismanal. Taken at higher-than-recommended doses or with some drugs, Hismanal can cause irregular heart rhythms or severe allergic reaction, the FDA said in a statement. Janssen said it was changing the label on the drug. ''Hismanal is associated with risks of death due to irregular heart rhythms when taken with certain other drugs and when used at higher than the recommended labeled dose,'' the FDA statement said. ''The new labeling provides information about a specific warning against simultaneously using Hismanal with other types of drugs such as the hypertension drug Posicor (mibefradil) and the antibiotics Biaxin (clarithromycin) and TAO (troleandomycin).'' Other drugs Hismanal should not be taken with include HIV protease inhibitor drugs such as Crixivan (indinavir), Norvir (ritonavir) and Viracept (nelfinavir), anti-depressants in the SSRI class such as Prozac, known generically as fluoxetine, Zoloft or sertraline and Paxil or paroxetine. It should also not be combined with Zyflo or zileuton, an asthma drug, or with grapefruit juice, which is known to make some drugs act more effectively in the body. ''These recommendations are based on the potential of these drugs and grapefruit juice to interfere with the body's handling and metabolism of Hismanal,'' the FDA said. ''The new labeling also emphasizes that patients with liver disorders would not take Hismanal.'' Hismanal, known generically as astemizole, is marketed by Janssen, a Johnson & Johnson Inc. (JNJ.N.) subsidiary. ''Worldwide experience indicates that Hismanal is safe and effective when used in accordance with its labeling,'' the letter to doctors from Janssen read. In May, Swedish doctors writing in the Lancet medical journal said astemizole and another antihistamine, loratadine, showed markedly high rates of sudden cardiac death and other severe reactions. The drugs are alternatives to terfenadine, which was the first prescription antihistamine to relieve hay fever symptoms without causing drowsiness. But its use is now restricted because of safety concerns. The FDA has proposed removing terfenadine from the market. Astemizole is already under review in Britain.